Literature DB >> 18184197

Defective response to Toll-like receptor 3 and 4 ligands by activated monocytes in chronic hepatitis C virus infection.

M C Villacres1, O Literat, M DeGiacomo, W Du, T Frederick, A Kovacs.   

Abstract

Toll-like receptors (TLR) have a critical role in innate immunity against pathogens. We investigated the cytokine response to TLR stimulation in peripheral blood cells of subjects infected with hepatitis C virus (HCV) and/or human immunodeficiency virus (HIV) in the Women Interagency HIV Study (WIHS) cohort. Interleukin (IL)-6 in response to TLR3 and TLR4 ligands such as polyinosinic-polycytidylic acid and lipopolysaccharide was significantly compromised in HCV-infected women. High spontaneous secretion of IL-6 suggested pre-existing cell activation as a factor mediating reduced responses to TLR3 and TLR4 stimulation. To a lesser extent, tumour necrosis factor-alpha and IL-1beta responses to TLR stimulation were also compromised. Monocytes, but not B cells or NK cells, were identified as the cell population spontaneously secreting cytokines and also as the cells responding to TLR stimulation. These results highlight a functional defect in antigen-presenting cells of women with HCV infection or co-infection. In women with existing HIV co-infection, decreased cytokine function of antigen-presenting cells suggests another mechanism contributing to immune dysfunction in addition to the HIV-associated CD4 defect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18184197      PMCID: PMC3118839          DOI: 10.1111/j.1365-2893.2007.00904.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  46 in total

1.  Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses.

Authors:  Georg M Lauer; Tam N Nguyen; Cheryl L Day; Gregory K Robbins; Theresa Flynn; Katherine McGowan; Eric S Rosenberg; Michaela Lucas; Paul Klenerman; Raymond T Chung; Bruce D Walker
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Murine retroviruses activate B cells via interaction with toll-like receptor 4.

Authors:  John C Rassa; Jennifer L Meyers; Yuanming Zhang; Rama Kudaravalli; Susan R Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

3.  Cytokine serum levels in patients with chronic HCV infection.

Authors:  Nick E Spanakis; George A Garinis; Evangelos C Alexopoulos; George P Patrinos; Panayotis G Menounos; Alexandra Sklavounou; Evangelos N Manolis; Vassilis G Gorgoulis; Dimitrios Valis
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

Review 4.  The hepatitis C virus persistence: how to evade the immune system?

Authors:  Nicole Pavio; Michael M C Lai
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

5.  Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugs.

Authors:  Alan Landay; Lorie Benning; James Bremer; Barbara Weiser; Harold Burger; Marek Nowicki; Andrea Kovacs
Journal:  J Infect Dis       Date:  2003-07-01       Impact factor: 5.226

6.  Persistent immune activation in HIV-1 infection is associated with progression to AIDS.

Authors:  Mette D Hazenberg; Sigrid A Otto; Birgit H B van Benthem; Marijke Th L Roos; Roel A Coutinho; Joep M A Lange; Dörte Hamann; Maria Prins; Frank Miedema
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

7.  Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation.

Authors:  Angela Dolganiuc; Karen Kodys; Andrea Kopasz; Christopher Marshall; Twan Do; Laszlo Romics; Pranoti Mandrekar; Maria Zapp; Gyongyi Szabo
Journal:  J Immunol       Date:  2003-06-01       Impact factor: 5.422

8.  Infection of primary human macrophages with hepatitis C virus in vitro: induction of tumour necrosis factor-alpha and interleukin 8.

Authors:  Marek Radkowski; Agnieszka Bednarska; Andrzej Horban; Janusz Stanczak; Jeffrey Wilkinson; Debra M Adair; Marek Nowicki; Jorge Rakela; Tomasz Laskus
Journal:  J Gen Virol       Date:  2004-01       Impact factor: 3.891

9.  Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection.

Authors:  Heiner Wedemeyer; Xiao-Song He; Michelina Nascimbeni; Anthony R Davis; Harry B Greenberg; Jay H Hoofnagle; T Jake Liang; Harvey Alter; Barbara Rehermann
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

10.  Toll-like receptor 4-dependent activation of dendritic cells by a retrovirus.

Authors:  Dalia Burzyn; John C Rassa; David Kim; Irene Nepomnaschy; Susan R Ross; Isabel Piazzon
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

View more
  20 in total

1.  Reconfigurable microfluidic device with integrated antibody arrays for capture, multiplexed stimulation, and cytokine profiling of human monocytes.

Authors:  Tam Vu; Ali Rahimian; Gulnaz Stybayeva; Yandong Gao; Timothy Kwa; Judy Van de Water; Alexander Revzin
Journal:  Biomicrofluidics       Date:  2015-08-06       Impact factor: 2.800

Review 2.  Macrophages in hepatitis B and hepatitis C virus infections.

Authors:  Mathis Heydtmann
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

3.  Involvement of TLR2-MyD88 in abnormal expression of miR-146a in peripheral blood monocytes of patients with chronic hepatitis C.

Authors:  Wen-Jing Zhang; Hua Wang; Qiao-Xia Tong; Sheng-Hua Jie; Dong-Liang Yang; Cheng Peng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-04-16

Review 4.  Role of circulatory microRNAs in the pathogenesis of hepatitis C virus.

Authors:  Iqra Almas; Samia Afzal; Muhammad Idrees; Muhammad Usman Ashraf; Iram Amin; Muhammad Shahid; Khadija Zahid; Sadia Zahid
Journal:  Virusdisease       Date:  2017-11-27

5.  Inhibitory effect of miR-125b on hepatitis C virus core protein-induced TLR2/MyD88 signaling in THP-1 cells.

Authors:  Cheng Peng; Hua Wang; Wen-Jing Zhang; Sheng-Hua Jie; Qiao-Xia Tong; Meng-Ji Lu; Dong-Liang Yang
Journal:  World J Gastroenterol       Date:  2016-05-07       Impact factor: 5.742

6.  Complete blood count, measures of iron status and inflammatory markers in inner-city African Americans with undiagnosed hepatitis C seropositivity.

Authors:  Hilary Ufearo; Khalid Kambal; Gladys O Onojobi; Mehdi Nouraie; Charles Agbemabiese; Sharmin Diaz; Anita Aggarwal; Zakari Aliyu; Robert E Taylor; Victor R Gordeuk
Journal:  Clin Chim Acta       Date:  2010-02-01       Impact factor: 3.786

7.  Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus.

Authors:  Andrea Kovacs; Roksana Karim; Wendy J Mack; Jiaao Xu; Zhi Chen; Eva Operskalski; Toni Frederick; Alan Landay; John Voris; La Shonda Spencer; Mary A Young; Phyllis C Tien; Michael Augenbraun; Howard D Strickler; Lena Al-Harthi
Journal:  J Infect Dis       Date:  2010-03-15       Impact factor: 5.226

Review 8.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 9.  Innate immune cell networking in hepatitis C virus infection.

Authors:  Banishree Saha; Gyongyi Szabo
Journal:  J Leukoc Biol       Date:  2014-07-07       Impact factor: 4.962

10.  Brief Report: CD14brightCD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy.

Authors:  Chelsey J Judge; Johan K Sandberg; Nicholas T Funderburg; Kenneth E Sherman; Adeel A Butt; Minhee Kang; Alan L Landay; Michael M Lederman; Donald D Anthony
Journal:  J Acquir Immune Defic Syndr       Date:  2016-11-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.